INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis
NASDAQ:IART - Nasdaq - US4579852082 - Common Stock - Currency: USD
IART gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of IART while its profitability can be described as average. IART has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
IART had positive earnings in the past year.
In the past year IART had a positive cash flow from operations.
IART had positive earnings in 4 of the past 5 years.
Each year in the past 5 years IART had a positive operating cash flow.
1.2 Ratios
The Return On Assets of IART (-13.65%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -48.20%, IART is in line with its industry, outperforming 49.73% of the companies in the same industry.
IART has a Return On Invested Capital of 4.68%. This is in the better half of the industry: IART outperforms 77.01% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IART is in line with the industry average of 8.03%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.65% | ||
| ROE | -48.2% | ||
| ROIC | 4.68% |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
1.3 Margins
Looking at the Operating Margin, with a value of 9.46%, IART is in the better half of the industry, outperforming 76.47% of the companies in the same industry.
IART's Operating Margin has declined in the last couple of years.
IART has a Gross Margin (57.24%) which is in line with its industry peers.
In the last couple of years the Gross Margin of IART has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.46% | ||
| PM (TTM) | N/A | ||
| GM | 57.24% |
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IART is still creating some value.
Compared to 1 year ago, IART has less shares outstanding
Compared to 5 years ago, IART has less shares outstanding
Compared to 1 year ago, IART has a worse debt to assets ratio.
2.2 Solvency
IART has an Altman-Z score of 1.06. This is a bad value and indicates that IART is not financially healthy and even has some risk of bankruptcy.
IART has a Altman-Z score (1.06) which is comparable to the rest of the industry.
IART has a Debt/Equity ratio of 1.18. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of IART (1.18) is worse than 81.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.06 |
ROIC/WACC0.86
WACC5.45%
2.3 Liquidity
IART has a Current Ratio of 1.23. This is a normal value and indicates that IART is financially healthy and should not expect problems in meeting its short term obligations.
IART's Current ratio of 1.23 is on the low side compared to the rest of the industry. IART is outperformed by 82.35% of its industry peers.
IART has a Quick Ratio of 1.23. This is a bad value and indicates that IART is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of IART (0.73) is worse than 89.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 0.73 |
3. Growth
3.1 Past
IART shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.85%.
IART shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.35% yearly.
IART shows a small growth in Revenue. In the last year, the Revenue has grown by 3.53%.
Measured over the past years, IART shows a small growth in Revenue. The Revenue has been growing by 1.20% on average per year.
EPS 1Y (TTM)-20.85%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%-28.57%
Revenue 1Y (TTM)3.53%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%-0.61%
3.2 Future
Based on estimates for the next years, IART will show a small growth in Earnings Per Share. The EPS will grow by 3.38% on average per year.
Based on estimates for the next years, IART will show a small growth in Revenue. The Revenue will grow by 3.92% on average per year.
EPS Next Y-10.77%
EPS Next 2Y-1.06%
EPS Next 3Y3.38%
EPS Next 5YN/A
Revenue Next Year3.34%
Revenue Next 2Y3.88%
Revenue Next 3Y3.92%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 6.08, the valuation of IART can be described as very cheap.
96.79% of the companies in the same industry are more expensive than IART, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of IART to the average of the S&P500 Index (26.93), we can say IART is valued rather cheaply.
A Price/Forward Earnings ratio of 5.44 indicates a rather cheap valuation of IART.
Based on the Price/Forward Earnings ratio, IART is valued cheaper than 98.40% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 35.31. IART is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.08 | ||
| Fwd PE | 5.44 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IART is valued cheaper than 93.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 8.64 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.06%
EPS Next 3Y3.38%
5. Dividend
5.1 Amount
IART does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
13.62
-0.5 (-3.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners100.14%
Inst Owner Change-0.41%
Ins Owners3.31%
Ins Owner Change2.01%
Market Cap1.06B
Analysts54.44
Price Target16.76 (23.05%)
Short Float %9.72%
Short Ratio5.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.27%
Min EPS beat(2)-6.76%
Max EPS beat(2)2.22%
EPS beat(4)3
Avg EPS beat(4)2.45%
Min EPS beat(4)-6.76%
Max EPS beat(4)11.12%
EPS beat(8)3
Avg EPS beat(8)-0.11%
EPS beat(12)6
Avg EPS beat(12)3.26%
EPS beat(16)8
Avg EPS beat(16)3.79%
Revenue beat(2)1
Avg Revenue beat(2)0.78%
Min Revenue beat(2)-1.58%
Max Revenue beat(2)3.14%
Revenue beat(4)1
Avg Revenue beat(4)-0.4%
Min Revenue beat(4)-2.51%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-0.95%
Revenue beat(12)2
Avg Revenue beat(12)-0.82%
Revenue beat(16)3
Avg Revenue beat(16)-0.75%
PT rev (1m)-1.71%
PT rev (3m)-18.44%
EPS NQ rev (1m)-21.72%
EPS NQ rev (3m)-23.75%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.03%
Revenue NQ rev (1m)-1.09%
Revenue NQ rev (3m)-0.74%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.08 | ||
| Fwd PE | 5.44 | ||
| P/S | 0.65 | ||
| P/FCF | N/A | ||
| P/OCF | 14.93 | ||
| P/B | 1.02 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.64 |
EPS(TTM)2.24
EY16.45%
EPS(NY)2.51
Fwd EY18.4%
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)0.91
OCFY6.7%
SpS20.87
BVpS13.37
TBVpS-9.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.65% | ||
| ROE | -48.2% | ||
| ROCE | 5.61% | ||
| ROIC | 4.68% | ||
| ROICexc | 5.16% | ||
| ROICexgc | 18.86% | ||
| OM | 9.46% | ||
| PM (TTM) | N/A | ||
| GM | 57.24% | ||
| FCFM | N/A |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexcg growth 3Y-1.99%
ROICexcg growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.18 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.06 | ||
| Cap/Depr | 79.68% | ||
| Cap/Sales | 7.29% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 23.48% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 0.73 | ||
| Altman-Z | 1.06 |
F-Score5
WACC5.45%
ROIC/WACC0.86
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.85%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%-28.57%
EPS Next Y-10.77%
EPS Next 2Y-1.06%
EPS Next 3Y3.38%
EPS Next 5YN/A
Revenue 1Y (TTM)3.53%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%-0.61%
Revenue Next Year3.34%
Revenue Next 2Y3.88%
Revenue Next 3Y3.92%
Revenue Next 5YN/A
EBIT growth 1Y-36.46%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year17.58%
EBIT Next 3Y10.16%
EBIT Next 5YN/A
FCF growth 1Y-130.53%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-65.94%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%